Halozyme Appoints Darren Snellgrove as Chief Financial Officer
Rhea-AI Summary
Halozyme (Nasdaq: HALO) appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove brings more than 30 years of financial leadership, including roles leading investor relations at Johnson & Johnson and serving as CFO for J&J's Pharmaceuticals business, a unit generating over $50 billion in annual revenue.
Positive
- Appointment effective June 8, 2026
- 30+ years of finance leadership experience
- Led investor relations at Johnson & Johnson
- Served as CFO for J&J Pharmaceuticals (>$50B annual revenue)
Negative
- None.
News Market Reaction – HALO
In the Apr 30 session, HALO gained 0.95%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Collaboration deal | Positive | +0.8% | Vertex global exclusive license for Hypercon™ with $15M upfront payment. |
| Mar 12 | CFO transition | Negative | -4.4% | Appointment of interim CFO while search for permanent finance head continues. |
| Mar 06 | FDA approval | Positive | +0.0% | U.S. FDA approval for TECVAYLI plus DARZALEX FASPRO multiple myeloma combo. |
| Feb 25 | Investor conferences | Neutral | -0.0% | CEO participation in multiple March investor conferences with webcasts. |
| Feb 17 | Earnings and guidance | Positive | -9.0% | Record 2025 revenue and reiterated 2026 guidance with strong royalty growth. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive fundamental or partnership news has sometimes met with muted or even negative price reactions, while CFO-related headlines have coincided with weakness.
Over recent months, Halozyme reported record 2025 revenue of $1.397B with strong royalty growth and reiterated robust 2026 guidance, yet the stock fell 9.01% after that earnings release. A subsequent FDA approval tied to partner TECVAYLI/DARZALEX FASPRO produced little share reaction. Strategic moves such as the Vertex Hypercon™ licensing deal ($15M upfront) saw only modest gains. CFO transition headlines in March were followed by a decline, so today’s permanent CFO appointment extends an ongoing finance leadership transition story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mr. Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and Chief Executive Officer.
"I am delighted to have a financial leader of Darren's experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadership across major portfolio investments and a strong, well-established record of investor engagement," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having Darren join our leadership team and contribute to the acceleration of value creation for our shareholders."
Mr. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson, a Fortune 50 healthcare company. In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.
Previously, Mr. Snellgrove served as Chief Financial Officer of Johnson & Johnson's Pharmaceuticals sector, where he provided global financial leadership for a business generating more than
Earlier in his career, Mr. Snellgrove held CFO and senior finance leadership roles across pharmaceutical R&D, innovation, and M&A at Johnson & Johnson, as well as progressive finance roles at Centocor prior to its acquisition.
"I am thrilled to join Halozyme at such an important time in the Company's evolution," said Mr. Snellgrove. "Halozyme's technology has dramatically improved the delivery of biologics for patients, and the company has built a broad technology portfolio with strong partners, durable royalty streams, and significant long‑term opportunity. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders."
Mr. Snellgrove holds an MBA from Villanova University and a BA Honors degree from the University of Southampton in
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme's future performance, durability of revenues, shareholder value creation and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures, costs and growth. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-darren-snellgrove-as-chief-financial-officer-302758516.html
SOURCE Halozyme Therapeutics, Inc.